In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The S2PLIT-UG score, a novel system identifying patients with a high risk of all-cause mortality following acute decompensation of heart failure, correlates with levels of sST2, hs-cTnI and NT-proBNP

Session HFA Discoveries - ePosters

Speaker Josip Andjelo Borovac

Event : HFA Discoveries 2020

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure – Epidemiology, Prognosis, Outcome
  • Session type : ePosters

Authors : JA Borovac (Split,HR), D D'amario (Rome,IT), D Glavas (Split,HR), Z Susilovic Grabovac (Split,HR), D Supe Domic (Split,HR), K Novak (Split,HR), A Bradaric (Split,HR), D Milicic (Zagreb,HR), D Duplancic (Split,HR), J Bozic (Split,HR)

Authors:
JA Borovac1 , D D'amario2 , D Glavas3 , Z Susilovic Grabovac3 , D Supe Domic4 , K Novak4 , A Bradaric4 , D Milicic5 , D Duplancic3 , J Bozic6 , 1University Hospital Center Split - Split - Croatia , 2Catholic University of the Sacred Heart - Fondazione Policlinico Universitario A. Gemelli IRCCS, Institute of Cardiology - Rome - Italy , 3University Hospital Center Split, Clinic for Cardiovascular Diseases - Split - Croatia , 4University Hospital Center Split, Department of Medical Laboratory Diagnostics - Split - Croatia , 5University Hospital Centre Zagreb, Department of Cardiovascular Diseases - Zagreb - Croatia , 6University of Split School of Medicine, Department of Pathophysiology - Split - Croatia ,

Citation:

Background: The S2PLIT-UG score has been recently published as a risk stratification tool for 1-year all-cause mortality among patients discharged after an acute decompensated heart failure (ADHF) event. This score stratifies ADHF patients into low, intermediate and high-risk categories. It is calculated by combining 6 variables collected at admission including estimated glomerular filtration rate, uric acid, left ventricular ejection fraction, sodium, systolic blood pressure and the history of heart failure-related hospitalizations. The study aimed to determine if patients identified as high-risk by the S2PLIT-UG score have higher circulating levels of biomarkers associated with poor prognosis such as soluble suppressor of tumorigenicity 2 (sST2), high-sensitivity cardiac troponin I (hs-cTnI) and N-terminal pro b-type natriuretic peptide (NT-proBNP). A secondary aim was to examine correlations of the S2PLIT-UG score with the aforementioned biomarkers.

Methods: A new validation cohort consisting of 96 patients hospitalized for ADHF and without acute coronary syndrome as an underlying culprit were consecutively included in the study during 2018-2019. All patients underwent standard transthoracic echocardiography, laboratory analyses of peripheral blood, and had their S2PLIT-UG score calculated with a high-risk score being defined as having =4 points. 

Results: One-quarter of patients (25%, N=24) in analyzed cohort were identified as a high-risk while 75% of patients (N=72) were non-high risk according to the S2PLIT-UG stratification system. Out of those designated as non-high risk, vast majority were low risk (70.8%, N=51) and 29.2% (N=21) were intermediate risk. High risk group did not significantly differ from non-high risk group of patients in terms of baseline characteristics including age (p=0.161), body mass index (p=0.437), sex distribution (p=0.637), smoking (p=0.626), dyslipidemia (p=0.898), diabetes mellitus (p=0.286) and presence of atrial fibrillation (p=0.288). Patients identified as high risk had significantly higher circulating levels of sST2 (65.2±50.2 vs. 34.8±26.4 ng/mL, p<0.001), hs-cTnI (142.2±239.0 vs. 42.9±94.0 ng/L, p=0.006), and NT-proBNP (13199±15325 vs. 5189±7295 pg/mL, p=0.001), compared to patients designated as non-high risk (Figure 1). As a continuous variable, the S2PLIT-UG score was in positive and significant correlation with circulating levels of sST2 (Pearson's r=0.420, p<0.001), hs-cTnI (r=0.281, p=0.007), and NT-proBNP (r=0.344, p=0.001).

Conclusions: A present study demonstrated that patients identified as high-risk according to S2PLIT-UG score had significantly higher circulating levels of biomarkers associated with poor prognosis, compared to non-high risk patients while S2PLIT-UG score correlated positively and significantly with circulating levels of sST2, hs-cTnI and NT-proBNP. These findings suggest a possible complementary value of the S2PLIT-UG score in the risk stratification of ADHF patients.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are